Lucid Diagnostics (LUCD) went public via an IPO on October 14th and opened at $12.75 per share. CEO Dr. Lishan Aklog says that the commercial stage medical diagnostics technology company is focused on patients with gastroesophageal reflux disease or GERD. What is next for LUCD and how will the stock continue to perform? Tune in for the full interview.
18 Oct 2021
Morning Trade Live
12 Aug 2022
Market On Close
03 Oct 2022
Trading 360
28 Sep 2022
Market On Close
28 Sep 2022
Market On Close
15 Sep 2022
Trading 360
03 Aug 2022